Inotrem gets clearance to launch phase 2 trial of Nangibotide in Covid-19 patients

This article was originally published here

For this study, Inotrem received a non-dilutive funding as part of the call for proposals PSPC Covid, financed by the Investments d’Avenir Program which managed on behalf of

The post Inotrem gets clearance to launch phase 2 trial of Nangibotide in Covid-19 patients appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply